BioCryst Pharmaceuticals Chief Financial Officer Stuart Grant has given notice that he is resigning from the drug developer.
Durham, North Carolina-based BioCryst (NASDAQ:BCRX) disclosed Friday in a filing with the U.S. Securities and Exchange Commission that Grant wishes to spend time this year traveling with his family following the loss of his son last year. Grant’s resignation is effective May 31 and the company said that he will be involved in the selection of his successor and the transition of his responsibilities to that person. After his resignation, Grant is also expected to continue his relationship with BioCryst through a consulting agreement. Grant has been BioCryst’s CFO since August 2007.
BioCryst is developing a flu treatment called Peramivir through a $180 million contract from the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health & Human Services. BioCryst, founded in Birmingham, Alabama, relocated its headquarters to Durham, where the company had much of its R&D operations.
